Table 1.
Characteristics of 1,205 Women Enrolled in the Mayo Baseline Study by Worst Outcome*
| Total | Not Done† | Inadequate | Normal | Other ‡ | Polyps | DPEM | Hyperplasia without atypia | Atypical Hyperplasia | Endometrial Cancer | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total, n (%) | 1,205 (100.0) | 118 (9.8) | 46 (3.8) | 652 (54.1) | 23 (1.9) | 158 (13.1) | 109 (9.1) | 30 (2.5) | 20 (1.7) | 49 (4.1) |
| Mean Age ±SD | 55.3 ± 8.0 | 55.6 ± 8.6 | 58.0 ± 7.0 | 54.2 ± 7.4 | 52.6 ± 7.1 | 58.1 ± 9.1 | 52.1 ± 5.0 | 57.0 ± 7.9 | 57.8 ± 7.8 | 63.4 ± 8.9 |
| Race/Ethnicity | ||||||||||
| Non-Hispanic White | 1,125 (93.4) | 112 (94.9) | 43 (93.5) | 610 (93.6) | 22 (95.7) | 147 (93.0) | 101 (92.7) | 27 (90.0) | 19 (95.0) | 44 (89.9) |
| Non-Hispanic Black | 11 (0.9) | 1 (0.9) | 1 (2.2) | 7 (1.1) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.0) |
| Hispanic | 18 (1.5) | 1 (0.9) | 1 (2.2) | 12 (1.8) | 0 (0.0) | 3 (1.9) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 0 (0.0) |
| Asian/Hawaiian Pacific Islander | 12 (1.0) | 1 (0.9) | 1 (2.2) | 7 (1.1) | 1 (4.3) | 1 (0.6) | (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.0) |
| Other/Unknown | 39 (3.2) | 2 (2.5) | 0 (0.0) | 16 (2.5) | 0 (0.0) | 6 (3.8) | 8 (7.3) | 3 (10.0) | 0 (0.0) | 3 (6.1) |
| Menopausal Status, n (%)§ | ||||||||||
| Pre-menopausal | 544 (45.2) | 52 (44.1) | 3 (6.5) | 314 (47.8) | 16 (69.6) | 50 (32.7) | 81 (74.3) | 15 (50.0) | 6 (30.0) | 7 (14.3) |
| Post-menopausal | 661 (54.8) | 66 (55.9) | 43 (93.5) | 343 (52.2) | 7 (30.4) | 103 (67.3) | 28 (25.7) | 15 (50.0) | 14 (70.0) | 42 (85.7) |
| Abnormal Bleeding, n (%)§ | ||||||||||
| None | 123 (10.2) | 13 (11.0) | 11 (23.9) | 67 (10.2) | 1 (4.4) | 23 (15.0) | 4 (3.7) | 0 (0.0) | 1 (5.0) | 3 (6.1) |
| Postmenopausal Bleeding | 567 (47.1) | 60 (50.9) | 33 (71.7) | 291 (44.3) | 7 (30.4) | 81 (52.9) | 27 (24.8) | 15 (50.0) | 13 (65.0) | 40 (81.6) |
| Abnormal Uterine Bleeding | 515 (42.7) | 45 (38.1) | 2 (4.4) | 299 (45.5) | 15 (65.2) | 49 (32.0) | 78 (71.6) | 15 (50.0) | 6 (30.0) | 6 (12.2) |
| Bleeding Episode (postmenopausal), n (%)* | ||||||||||
| Recurrent | 323 (59.5) | 32 (54.2) | 14 (46.7) | 154 (56.0) | 3 (42.9) | 48 (60.8) | 19 (73.1) | 11 (73.3) | 12 (100.0) | 30 (75.0) |
| Initial | 220 (40.5) | 27 (45.8) | 16 (53.3) | 121 (44.0) | 4 (57.1) | 31 (39.2) | 7 (26.9) | 4 (26.7) | 0 (0.0) | 10 (25.0) |
| Abnormal Uterine Bleeding Type (premenopausal), n (%)‖ | ||||||||||
| Menorrhagia | 160 (31.1) | 13 (28.9) | 0 (0.0) | 106 (35.5) | 2 (13.3) | 12 (24.5) | 22 (28.2) | 3 (20.0) | 2 (33.3) | 0 (0.0) |
| Metrorrhagia | 110 (21.4) | 15 (33.3) | 1 (50.0) | 61 (20.4) | 4 (26.7) | 12 (24.5) | 11 (14.1) | 4 (26.7) | 0 (0.0) | 2 (33.3) |
| Menometrorrhagia | 196 (38.1) | 9 (20.0) | 1 (50.0) | 106 (35.5) | 6 (40.0) | 20 (40.8) | 39 (50.0) | 7 (46.7) | 4 (66.7) | 4 (66.7) |
| Anovulatory Bleeding | 25 (4.9) | 1 (2.2) | 0 (0.0) | 15 (5.0) | 0 (0.0) | 3 (6.1) | 5 (6.4) | 1 (6.7) | 0 (0.0) | 0 (0.0) |
| Other | 24 (4.7) | 7 (15.6) | 0 (0.0) | 11 (3.7) | 3 (20.0) | 2 (4.1) | 1 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Current Tamoxifen Use, n (%)‖ | ||||||||||
| No | 1,148 (95.3) | 118 (100.0) | 41 (89.1) | 619 (94.2) | 21 (91.3) | 145 (94.8) | 105 (96.3) | 30 (100.0) | 20 (100.0) | 49 (100.0) |
| Yes | 57 (4.7) | 0 (0.0) | 5 (10.9) | 38 (5.8) | 2 (8.7) | 8 (5.2) | 4 (3.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Hormone Replacement Therapy Use, n (%)‖ | ||||||||||
| Never | 811 (67.3) | 86 (72.9) | 29 (63.0) | 434 (66.1) | 12 (52.2) | 97 (63.4) | 84 (77.1) | 17 (56.7) | 15 (75.0) | 37 (75.5) |
| Former | 144 (12.0) | 11 (9.3) | 5 (10.9) | 75 (11.4) | 1 (4.4) | 29 (19.0) | 8 (7.3) | 4 (13.3) | 3 (15.) | 8 (16.3) |
| Current | 250 (20.8) | 21 (17.8) | 12 (26.1) | 148 (22.5) | 10 (43.5) | 27 (17.6) | 17 (15.6) | 9 (30.0) | 2 (10.0) | 4 (8.2) |
| Mean Body Mass Index ± SD§ | 30.2 ± 8.0 | 28.0 ± 6.4 | 30.3 ± 8.7 | 29.5 ± 7.7 | 28.9 ± 7.5 | 31.2 ± 8.1 | 30.8 ± 7.5 | 30.9 ± 8.0 | 41.9 ± 7.8 | 34.2 ± 10.4 |
| Hypertension, n (%)§ | ||||||||||
| No | 912 (75.7) | 87 (73.7) | 31 (67.4) | 526 (80.1) | 17 (73.9) | 114 (74.5) | 82 (75.2) | 19 (63.3) | 8 (40.0) | 28 (57.1) |
| Yes | 293 (24.3) | 31 (26.3) | 15 (32.6) | 131 (19.9) | 6 (26.1) | 39 (25.5) | 27 (24.8) | 11 (36.7) | 12 (60.0) | 21 (42.9) |
| Type II Diabetes, n (%)‖ | ||||||||||
| No | 1,121 (93.0) | 114 (96.6) | 39 (84.8) | 621 (94.5) | 21 (91.3) | 141 (92.2) | 103 (94.5) | 26 (86.7) | 16 (80.0) | 40 (81.6) |
| Yes | 84 (7.0) | 4 (3.4) | 7 (15.2) | 36 (5.5) | 2 (8.7) | 12 (7.8) | 6 (5.5) | 4 (13.3) | 4 (20.0) | 9 (18.4) |
| Smoking Status, n (%) | ||||||||||
| Never | 828 (68.8) | 71 (60.2) | 32 (71.1) | 463 (70.5) | 20 (87.0) | 93 (60.8) | 73 (67.6) | 23 (76.7) | 14 (70.0) | 39 (79.6) |
| Current | 81 (6.7) | 7 (5.9) | 4 (8.9) | 47 (7.2) | 0 (0.0) | 12 (7.8) | 8 (7.4) | 0 (0.0) | 1 (5.0) | 2 (4.1) |
| Former | 294 (24.4) | 40 (33.9) | 9 (20.0) | 147 (22.4) | 3 (13.0) | 48 (31.4) | 27 (25.0) | 7 (23.3) | 5 (25.0) | 8 (16.3) |
| Past Oral Contraception Use, n (%) | ||||||||||
| No | 315 (27.2) | 40 (34.8) | 7 (16.3) | 162 (25.5) | 5 (22.7) | 46 (30.7) | 23 (22.6) | 8 (28.6) | 6 (31.6) | 18 (40.9) |
| Yes | 843 (72.8) | 75 (65.2) | 36 (83.7) | 473 (74.5) | 17 (77.3) | 104 (69.3) | 79 (77.4) | 20 (71.4) | 13 (68.4) | 26 (59.1) |
| Parity, n (%)‖ | ||||||||||
| Nulliparous | 199 (16.5) | 29 (24.6) | 7 (15.2) | 89 (13.6) | 6 (26.1) | 33 (21.6) | 16 (14.8) | 5 (16.7) | 4 (20.0) | 10 (20.4) |
| Parous | 1,005 (83.5) | 89 (75.4) | 39 (84.8) | 556 (86.4) | 17 (73.9) | 120 (78.4) | 92 (85.2) | 25 (83.3) | 16 (80.0) | 39 (79.6) |
| Family History of EC, n (%) | ||||||||||
| No | 1,097 (91.0) | 105 (89.0) | 40 (87.0) | 595 (90.6) | 20 (87.0) | 141 (92.2) | 101 (92.7) | 30 (100.0) | 20 (100.0) | 45 (91.8) |
| Yes | 108 (9.0) | 13 (11.0) | 6 (13.0) | 62 (9.4) | 3 (13.0) | 12 (7.8) | 8 (7.3) | 0 (0.0) | 0 (0.0) | 4 (8.2) |
*
Worst outcome corresponds to the worst pathology of either the endometrial biopsy or hysterectomy specimen at baseline
†
Not clinically indicated
‡
Other benign uterine conditions such as endometriosis, fibroids
§
p<0.0001
‖
p<0.05
Abbreviations: DPEM, Disordered proliferative endometrium; SD, standard deviation; EC, endometrial cancer
Note: Values may not sum to 100% due to rounding